Inoxon

For intravenous (IV) administration, reconstitute the powder with an appropriate diluent (e.g., Sterile Water for Injection, 0.9% Sodium Chloride Injection) and infuse over 30 minutes. For intramuscular (IM) administration, reconstitute with 1% Lidocaine HCl solution and inject deep into a large muscle mass (e.g., gluteus maximus). Do not administer IV calcium-containing solutions simultaneously with ceftriaxone, especially in neonates.

Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) located inside the bacterial cell wall. This binding prevents the cross-linking of peptidoglycan chains, which is essential for maintaining the integrity and rigidity of the bacterial cell wall, leading to cell lysis and bacterial death.

• Hypersensitivity to ceftriaxone, any other cephalosporin, or any component of the formulation.
• History of severe hypersensitivity reactions (e.g., anaphylaxis) to any other beta-lactam antibiotic (e.g., penicillin).
• Neonates (≤28 days old) with hyperbilirubinemia, especially premature neonates, due to the risk of bilirubin encephalopathy.
• Neonates (≤28 days old) receiving intravenous calcium-containing solutions or products due to the risk of precipitation.

Store the dry powder vials at a controlled room temperature, below 30°C (86°F), protected from light and moisture. Reconstituted solutions are stable for a limited time (e.g., 6 hours at room temperature or 24 hours under refrigeration) depending on the diluent used and manufacturer's instructions; always use freshly prepared solutions when possible.

In cases of overdose, symptoms may include nausea, vomiting, diarrhea, and potentially neurological disturbances such as seizures. There is no specific antidote. Treatment is supportive and symptomatic. Hemodialysis or peritoneal dialysis is generally not effective in removing ceftriaxone from the body.

Pregnancy Category B. Studies in animals have shown no evidence of fetal harm, but there are no adequate and well-controlled studies in pregnant women. Ceftriaxone should be used during pregnancy only if clearly needed and the potential benefits outweigh the potential risks to the fetus. It is excreted in breast milk in low concentrations; caution should be exercised when Inoxon is administered to a nursing woman.

• Hypersensitivity to ceftriaxone, any other cephalosporin, or any component of the formulation.
• History of severe hypersensitivity reactions (e.g., anaphylaxis) to any other beta-lactam antibiotic (e.g., penicillin).
• Neonates (≤28 days old) with hyperbilirubinemia, especially premature neonates, due to the risk of bilirubin encephalopathy.
• Neonates (≤28 days old) receiving intravenous calcium-containing solutions or products due to the risk of precipitation.

Store the dry powder vials at a controlled room temperature, below 30°C (86°F), protected from light and moisture. Reconstituted solutions are stable for a limited time (e.g., 6 hours at room temperature or 24 hours under refrigeration) depending on the diluent used and manufacturer's instructions; always use freshly prepared solutions when possible.

In cases of overdose, symptoms may include nausea, vomiting, diarrhea, and potentially neurological disturbances such as seizures. There is no specific antidote. Treatment is supportive and symptomatic. Hemodialysis or peritoneal dialysis is generally not effective in removing ceftriaxone from the body.

Pregnancy Category B. Studies in animals have shown no evidence of fetal harm, but there are no adequate and well-controlled studies in pregnant women. Ceftriaxone should be used during pregnancy only if clearly needed and the potential benefits outweigh the potential risks to the fetus. It is excreted in breast milk in low concentrations; caution should be exercised when Inoxon is administered to a nursing woman.